Core Insights - LIXTE Biotechnology Holdings, Inc. announced the online publication of pre-clinical data demonstrating the conversion of its lead compound LB-100 into the active form endothall, which is effective in cancer treatment when combined with immunotherapy [1][4] - The discovery of an enzyme that mediates this conversion could serve as a potential biomarker to identify patients likely to respond to LB-100 [2] - Clinical trials for LB-100 are currently underway for ovarian and colorectal cancer, with the new data aiding in optimizing patient selection for future trials [4] Group 1: Scientific Findings - The Netherlands Cancer Institute identified an enzyme that facilitates the conversion of LB-100 into endothall, suggesting its role as a potential biomarker [2] - Research from BioPharmaWorks LLC indicates that LB-100 converts into endothall through hydrolysis, although this process is slow under physiological conditions [3] Group 2: Company Overview - LIXTE is focused on developing new cancer therapies, with LB-100 being a first-in-class PP2A inhibitor that has shown good tolerance in cancer patients [4] - The company claims that LB-100 has the potential to improve outcomes for patients undergoing various chemotherapies or immunotherapies, supported by a comprehensive patent portfolio [4]

Core Viewpoint - LIXTE Biotechnology Holdings, Inc. has initiated a clinical trial combining its compound LB-100 with GSK's immunotherapy Dostarlimab to treat ovarian clear cell cancer, with the first patient dosed at the Lurie Cancer Center [1][2][3]. Group 1: Clinical Trial Details - The clinical trial is led by Dr. Emily M. Hinchcliff at the Lurie Cancer Center, a National Cancer Institute-designated Comprehensive Cancer Center [2]. - Patient recruitment is currently underway, and the trial aims to assess the effectiveness of combining LB-100 with Dostarlimab in treating ovarian clear cell carcinoma, a condition with significant unmet medical needs [3]. - The trial was initially launched in January 2024 at The University of Texas MD Anderson Cancer Center, directed by Dr. Amir Jazaeri [3]. Group 2: Company Overview - LIXTE is a clinical-stage pharmaceutical company focused on developing new cancer therapies, with its lead compound LB-100 being a first-in-class PP2A inhibitor [4]. - LB-100 has shown potential to improve outcomes for patients undergoing various chemotherapies or immunotherapies, supported by extensive preclinical data [4]. - The company operates in a unique field of cancer biology known as activation lethality, and it holds a comprehensive patent portfolio to protect its innovations [4].

Core Viewpoint - LIXTE Biotechnology Holdings, Inc. has initiated a clinical trial combining its compound LB-100 with GSK's immunotherapy Dostarlimab to treat ovarian clear cell cancer, with the first patient dosed at the Lurie Cancer Center [1][2][3]. Group 1: Clinical Trial Details - The clinical trial is led by Dr. Emily M. Hinchcliff at the Lurie Cancer Center, a National Cancer Institute-designated Comprehensive Cancer Center [2]. - Patient recruitment is currently underway, and the trial aims to assess the effectiveness of combining LB-100 with Dostarlimab in treating ovarian clear cell carcinoma, which has a high unmet medical need [3]. - The trial was initially launched in January 2024 at The University of Texas MD Anderson Cancer Center, directed by Dr. Amir Jazaeri [3]. Group 2: Company Overview - LIXTE is a clinical-stage pharmaceutical company focused on developing new cancer therapies, with its lead compound LB-100 being a first-in-class PP2A inhibitor [4]. - LB-100 has shown potential to improve outcomes for patients undergoing various chemotherapies or immunotherapies, supported by extensive preclinical data [4]. - The company operates in a unique field of cancer biology known as activation lethality, with a comprehensive patent portfolio protecting its innovations [4].

Core Viewpoint - LIXTE Biotechnology Holdings, Inc. has successfully closed a registered direct offering of 434,784 shares of common stock at a price of $2.415 per share, along with a concurrent private placement of unregistered warrants [1][2]. Group 1: Offering Details - The total gross proceeds from the offering amount to approximately $1,050,000, before deducting fees and expenses [2]. - The warrants issued in the private placement allow for the purchase of up to 434,784 shares at an exercise price of $2.29 per share, exercisable for five years [1][2]. Group 2: Regulatory and Compliance Information - The shares were offered under a "shelf" registration statement filed with the SEC, which became effective on May 2, 2024 [3]. - The warrants and the underlying shares have not been registered under the Securities Act, limiting their sale in the U.S. without an effective registration statement or applicable exemption [4]. Group 3: Company Overview - LIXTE is a clinical-stage pharmaceutical company focused on developing cancer therapies, particularly its lead clinical compound, LB-100, which is a first-in-class PP2A inhibitor [6]. - LB-100 has shown potential to improve outcomes for patients undergoing various cancer treatments and is part of a new treatment paradigm in cancer biology [6].

Core Viewpoint - LIXTE Biotechnology Holdings, Inc. has announced a registered direct offering of 434,784 shares of common stock at a price of $2.415 per share, along with a concurrent private placement of unregistered warrants to purchase the same number of shares at an exercise price of $2.29 per share, expected to raise approximately $1.05 million in gross proceeds [1][2]. Group 1: Offering Details - The offering consists of 434,784 shares of common stock priced at $2.415 per share, with a concurrent issuance of warrants at an exercise price of $2.29 per share, exercisable for five years [1]. - The expected gross proceeds from the offering are approximately $1.05 million, before deducting fees and expenses [2]. - The closing of the offering is anticipated to occur on or about February 12, 2025, subject to customary closing conditions [1]. Group 2: Regulatory and Legal Information - The shares are being offered under a "shelf" registration statement on Form S-3, which became effective on May 2, 2024 [3]. - The warrants are issued in a private placement and have not been registered under the Securities Act, meaning they cannot be offered or sold in the U.S. without an effective registration statement or applicable exemption [4]. Group 3: Company Overview - LIXTE Biotechnology Holdings, Inc. is a clinical-stage pharmaceutical company focused on developing cancer therapies, particularly its lead clinical compound LB-100, which has shown potential in improving outcomes for patients undergoing chemotherapy or immunotherapy [6]. - LB-100 is part of a new treatment paradigm in cancer biology known as activation lethality, and the company holds a comprehensive patent portfolio for its innovative approach [6].

Core Viewpoint - LIXTE Biotechnology Holdings, Inc. has withdrawn its Registration Statement for a public offering, indicating a shift in its funding strategy at this time [1]. Company Overview - LIXTE Biotechnology Holdings, Inc. is a clinical-stage pharmaceutical company focused on developing new cancer therapies [3]. - The company’s lead clinical candidate, LB-100, is a first-in-class PP2A inhibitor that has shown good tolerance in cancer patients and potential to enhance outcomes during chemotherapy or immunotherapy [3]. - LIXTE operates in a unique area of cancer biology known as activation lethality, with no known competitors and a comprehensive patent portfolio [3]. - Ongoing proof-of-concept clinical trials are part of LIXTE's innovative approach to cancer treatment [3].

Core Insights - LIXTE Biotechnology Holdings has received a Notice of Allowance for a patent related to combining its LB-100 compound with various cancer immunotherapies, enhancing its intellectual property portfolio [1][2][5] - The company is conducting clinical trials for LB-100 in combination with immunotherapies at notable institutions, including the Netherlands Cancer Institute and MD Anderson Cancer Center [3][4] - LIXTE's LB-100 is positioned as a first-in-class PP2A inhibitor, which is being tested for its potential to improve cancer treatment outcomes [6][7] Patent and Intellectual Property - The newly awarded patent supports LIXTE's commitment to innovative cancer research and treatment solutions [2] - An exclusive patent license agreement with the National Institute of Neurological Disorders and Stroke and the National Cancer Institute allows LIXTE to explore novel combination therapies [5] Clinical Trials and Research - LB-100 is being tested in combination with Roche's atezolizumab for metastatic colon cancer and GSK's dostarlimab-gxly for ovarian clear cell carcinoma [4] - The company is advancing a new treatment paradigm in cancer biology known as activation lethality, with ongoing proof-of-concept trials for various cancer types [7]

-Collaboration with NKI and Funding Support for New Colorectal Cancer Clinical Trial by Major Pharma Company- -Distinguished Oncologist Jan Schellens Joins LIXTE as Chief Medical Officer- -Preclinical Data Published in Journal EMBO Reports Shows LB-100 as Potentially Enhancing the Benefit of Immunotherapy- -LIXTE to Present at Two Upcoming Investor Conferences- PASADENA, CA, Aug. 19, 2024 (GLOBE NEWSWIRE) -- LIXTE Biotechnology Holdings, Inc. ("LIXTE" or the "Company") (Nasdaq: LIXT and LIXTW), a clinical-s ...

-Company to Present August 20 at Investor Summit Summer 2024 Virtual Conference; and September 9-11 at H.C. Wainwright 26th Annual Global Investment Conference- PASADENA, CALIF., Aug. 15, 2024 (GLOBE NEWSWIRE) -- LIXTE Biotechnology Holdings, Inc. ("LIXTE" or the "Company") (Nasdaq: LIXT and LIXTW), a clinical stage pharmaceutical company, today announced it will be presenting at two investor conferences: The Investor Summit Summer 2024 Virtual Conference Tuesday, August 20, 2024, at 2 p.m. EDT/11 a.m. PDT. ...

Clinical trial to test recent findings that show LIXTE's lead clinical compound, LB-100, increases recognition of colon cancer cells by the immune system "This is an exciting new clinical trial," said Neeltje Steeghs, M.D., Ph.D., medical oncologist from NKI and Antoni van Leeuwenhoek Hospital, who is serving as principal investigator of the trial. "Only about 15% of colon cancers are responsive to immunotherapy, the so-called MSI High cancers. However, approximately 85% of colon cancers are MSI Low where i ...